SEC Form 4 · accession 0001127602-19-004918
GILEAD SCIENCES, INC. · GILD
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Laura Hamill
Officer — EVP, Worldwide Commercial Ops
Period of report
Feb 6, 2019
Accepted (ET)
Feb 8, 2019 · 7:20 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0000882095
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Non-qualified Stock Option (Right to Buy)F1 | $68.75 | Feb 6, 2019 | A | 63,100 | A | — | Feb 6, 2029 | Common Stock | 63,100 | 63,100 | D |
| Restricted Stock UnitF2,F3 | — | Feb 6, 2019 | A | 13,640 | A | — | — | Common Stock | 13,640 | 46,435 | D |
Explanation of responses
- F1The options have a four year vesting schedule. 25% of the options will vest on the first anniversary date of the grant. The balance will vest 6.25% quarterly thereafter until fully vested.
- F2Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock.
- F3The restricted stock units have a four-year vesting schedule. 25% vest on each yearly anniversary of the date of grant until fully vested.